N-Tridecanoylglycine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Tridecanoylglycine
• 英文别名: Tridecanoylglycine；2-(tridecanoylamino)acetic acid
• 化学式: C₁₅H₂₉NO₃
• 分子量: 271.4
• InChiKey: BTHNNPTZHGZNAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  19
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  十三酸 在 草酰氯 、 碳酸氢钠 、 lithium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 氯仿 、 水 为溶剂， 反应 4.0h， 生成 N-Tridecanoylglycine
  参考文献：
  名称：

  Structure and Thermotropic Phase Behavior of a Homologous Series ofN-Acylglycines: Neuroactive and Antinociceptive Constituents of Biomembranes

  摘要：

  N-Acylglycines (NAGs) with different acyl chains have been found in the mammalian brain and other tissues. They exhibit significant biological and pharmacological properties and appear to play important roles in communication and signaling pathways within and between cells. In view of this, a homologous series of NAGs have been synthesized and characterized in the present study. Differential scanning calorimetric (DSC) studies show that the transition enthalpies and entropies of dry as well as hydrated NAGs exhibit a linear dependence on the acyl chain length. Most of the NAGs show a minor transition below the chain-melting phase transition, suggesting the presence of polymorphism in the solid state. Structures of N-myristoylglycine (NMG) and N-palmitoylglycine (NPG) were solved in monoclinic system with C2/c and P2(1) space groups, respectively. Analysis of the crystal structures show that NAGs are organized in a bilayer fashion, with head-to-head (and tail-to-tail) arrangement of molecules. The acyl chains in both structures are essentially perpendicular to the bilayer plane, which is consistent with a lack of oddeven alternation in the thermodynamic properties. The bilayer is stabilized by strong hydrogen bonding interactions between -COOH groups of the molecules from opposite leaflets as well as NH center dot center dot center dot O hydrogen bonds between the amide groups of adjacent molecules in the same leaflet and dispersion interactions among the acyl chains. Powder X-ray diffraction data show that the d-spacings for the NAGs with different acyl chains (n = 820) exhibit a linear dependence on the chain length, suggesting that all the NAGs investigated here adopt a similar packing arrangement in the crystal lattice. These observations are relevant for understanding the role of N-acylglycines in biological membranes.

  DOI：

  10.1021/cg500481u

文献信息

• [EN] BINDING-SITE MODIFIED LECTINS AND USES THEREOF<br/>[FR] LECTINES DE SITE DE LIAISON MODIFIÉES ET USAGE CORRESPONDANT
  申请人：SMARTCELLS INC

  公开号：WO2010088261A1

  公开（公告）日：2010-08-05

  In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one covalently linked affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with glucose for binding with the lectins at said binding sites and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of glucose. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label.

  在一个方面，该公开提供了包括多价凝集素的交联材料，其中该多价凝集素具有至少两个葡萄糖结合位点，其中该凝集素包括至少一个与亲和配体共价连接的亲和配体，该亲和配体能够与至少一个所述结合位点中的葡萄糖竞争结合；以及包括绑定到共轭框架的两个或更多个独立亲和配体的共轭物，其中这两个或更多个亲和配体与葡萄糖在所述结合位点上与凝集素竞争结合，其中由于不同共轭物上的凝集素和亲和配体之间的非共价相互作用，共轭物在材料内交联。这些材料旨在根据所需葡萄糖浓度释放共轭物的量。根据最终应用，在各种实施例中，共轭物还可以包括药物和/或可检测标记。
• DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO
  申请人：Chen Zhiyu

  公开号：US20130190475A1

  公开（公告）日：2013-07-25

  The present invention relates to methods for synthesizing compounds of formula I or pharmaceutically acceptable salts thereof: I wherein each of X, Alk 1 , Alk 2 , and W are as defined and described herein.

  本发明涉及合成式I化合物或其药用可接受盐的方法：其中X、Alk1、Alk2和W各自如本文所定义和描述。
• Process for converting primary amidoalcohols to amidocarboxylic acids in high yield
  申请人：Conopco, Inc.

  公开号：US07307187B1

  公开（公告）日：2007-12-11

  The invention relates to an improved process for oxidizing a primary amidoalcohol to the corresponding amidocarboxylic acid in high yield.

  本发明涉及一种改进的方法，用于将一种原始的氨基醇氧化为相应的酰胺羧酸，高收率。
• [EN] CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS<br/>[FR] CONJUGUÉS POUR UNE RÉACTIVITÉ SÉLECTIVE À DES DIOLS VICINAUX
  申请人：PROTOMER TECH INC

  公开号：WO2021202802A1

  公开（公告）日：2021-10-07

  Embodiments of the present disclosure relate to sensors that can selectively bind to specific vicinal diols in the presence of other diols. These boronated vicinal diol-responsive sensor compounds can sense levels of specific vicinal diols and respond to these molecules in the body. In certain embodiments, the vicinal diol is a cis diol, for example, a hexose such as glucose. In certain embodiments the sensors are conjugated to a drug substance, and the sensors may change the biophysical characteristics, pharmacokinetics, and/or activity of the drug substance in response to the vicinal diol. The drug substance may be or include a polypeptide, such as an insulin, a human endocrine or incretin peptide, or an analogue thereof, and may contain one or more modified amino acids containing a vicinal diol-responsive sensor.

  本公开的实施例涉及传感器，该传感器可以在其他二醇存在的情况下选择性地结合特定的邻二醇。这些硼化邻二醇响应传感器化合物可以感知特定邻二醇的水平，并对这些分子在体内做出反应。在某些实施例中，邻二醇是顺式二醇，例如六糖，如葡萄糖。在某些实施例中，传感器与药物物质结合，传感器可以改变药物物质的生物物理特性，药代动力学和/或活性，以响应邻二醇。药物物质可以是或包括多肽，例如胰岛素，人类内分泌或肠促素肽或其类似物，并且可能包含一个或多个含有邻二醇响应传感器的修饰氨基酸。
• Transglutaminase mediated conjugation of peptides
  申请人：Johansen Langeland Nils

  公开号：US20070105770A1

  公开（公告）日：2007-05-10

  Methods for conjugating peptides are provided comprising i) reacting a peptide with a first compound comprising a functional group in the presence of a transglutaminase capable of incorporating said compound into the peptide to form a transaminated peptide, and ii) reacting said transaminated peptide with e.g. a functionalized polymer capable of reacting with the functional group incorporated in the peptide in the enzymatic reaction.

  提供了肽共轭的方法，包括：i)在转谷氨酰胺酶的存在下，将肽与含有官能基的第一化合物反应，使该化合物被并入肽中，形成转氨基化肽；ii)将所述转氨基化肽与具有官能基的聚合物反应，使其与在酶催化反应中并入肽中的官能基发生反应。